QCG
CABA icon

Quadrant Capital Group’s Cabaletta Bio CABA Stock Holding History

Quadrant Capital Group’s Portfolio CABA Stock Details CABA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-6,495
Closed -$17.5K – 1452
2026
Q1 		$17.5K Buy
+6,495
New +$18K ﹤0.01% 2040

Other funds holding CABA

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Quadrant Capital Group's CABA Position: Q2 2026 in Review

Quadrant Capital Group sold out of Cabaletta Bio (CABA) in Q2 2026, closing a stake of 6,495 shares — an estimated $17.5K sold.

Quadrant Capital Group first reported a position in CABA in Q1 2026 and held it in 1 quarter. The position peaked at $17.5K in Q1 2026. 140 funds tracked by Wall St. Rank hold CABA as of Q2 2026.

  • Quadrant Capital Group reported no remaining Cabaletta Bio position as of Q2 2026 after selling out during the quarter.
  • Quadrant Capital Group sold 6,495 Cabaletta Bio shares in Q2 2026, an estimated $17.5K.
  • Quadrant Capital Group first reported a position in Cabaletta Bio in Q1 2026 and held it in 1 quarter.
  • Quadrant Capital Group's Cabaletta Bio position peaked at $17.5K in Q1 2026.
  • 140 funds tracked by Wall St. Rank held Cabaletta Bio as of Q2 2026.

Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.